FROM:
J Natl Cancer Inst 1999 (Aug 4); 91 (15): 1331
Zackheim HS
The epidemiologic literature in the English language regarding
intake of tomatoes and tomato-based products and blood lycopene
(a compound derived predominantly from tomatoes) level in
relation to the risk of various cancers was reviewed.
Among 72 studies identified, 57 reported inverse associations
between tomato intake or blood lycopene level and the risk of
cancer at a defined anatomic site; 35 of these inverse
associations were statistically significant. No study indicated
that higher tomato consumption or blood lycopene level
statistically significantly increased the risk of cancer at any
of the investigated sites.
About half of the relative risks for comparisons of high with low
intakes or levels for tomatoes or lycopene were approximately 0.6
or lower. The evidence for a benefit was strongest for cancers of
the prostate, lung, and stomach. Data were also suggestive of a
benefit for cancers of the pancreas, colon and rectum, esophagus,
oral cavity, breast, and cervix.
Because the data are from observational studies, a cause-effect
relationship cannot be established definitively. However, the
consistency of the results across numerous studies in diverse
populations, for case-control and prospective studies, and for
dietary-based and blood-based investigations argues against bias
or confounding as the explanation for these findings. Lycopene
may account for or contribute to these benefits, but this
possibility is not yet proven and requires further study.
Numerous other potentially beneficial compounds are present in
tomatoes, and, conceivably, complex interactions among multiple
components may contribute to the anticancer properties of
tomatoes. The consistently lower risk of cancer for a variety of
anatomic sites that is associated with higher consumption of
tomatoes and tomato-based products adds further support for
current dietary recommendations to increase fruit and vegetable
consumption.